OncoMatch/Clinical Trials/NCT05761366
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
Is NCT05761366 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Al18F-PSMA-BCH PET/CT for malignancy.
Treatment: Al18F-PSMA-BCH PET/CT — In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Prostate Cancer
Urothelial Carcinoma
Colorectal Cancer
Head and Neck Squamous Cell Carcinoma
Mesothelioma
Hepatocellular Carcinoma
Cholangiocarcinoma
Multiple Myeloma
Biomarker criteria
Required: PSMA (FOLH1) positive-expressing
PSMA positive-expressing tumors
Prior therapy
Cannot have received: experimental drug or device
Received experimental drug or device within 1 month
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05761366 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior experimental drug or device disqualifies patients from enrollment.
Does this trial require FOLH1?
Yes, FOLH1 positive-expressing is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify